{"id":"NCT03403712","sponsor":"Helsinn Healthcare SA","briefTitle":"A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer","officialTitle":"A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Phase 3b Study to Assess the Safety and to Describe the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination (IV NEPA FDC) Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination (AkynzeoÂ®) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Initial and Repeated Cycles of Anthracycline-cyclophosphamide (AC) Chemotherapy in Women With Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-16","primaryCompletion":"2018-09-19","completion":"2018-09-19","firstPosted":"2018-01-19","resultsPosted":"2020-04-15","lastUpdate":"2020-06-01"},"enrollment":404,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Chemotherapy-induced Nausea and Vomiting"],"interventions":[{"type":"DRUG","name":"fosnetupitant/ palonosetron","otherNames":["IV NEPA FDC"]},{"type":"DRUG","name":"netupitant/palonosetron","otherNames":["Akynzeo capsules"]},{"type":"DRUG","name":"dexamethasone","otherNames":[]}],"arms":[{"label":"Test group","type":"EXPERIMENTAL"},{"label":"Control group","type":"ACTIVE_COMPARATOR"}],"summary":"Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intravenous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion \\[test\\] versus oral netupitant/palonosetron (300 mg/0.5 mg) combination \\[control\\]; each administered with oral dexamethasone prior to initial and repeated cycles of AC chemotherapy in female breast cancer patients.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent AEs at Cycle 1","timeFrame":"At the end of Cycle 1 (each cycle is 21 days)","effectByArm":[{"arm":"Test Group","deltaMin":121,"sd":null},{"arm":"Control Group","deltaMin":122,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":40,"countries":["United States","Georgia"]},"refs":{"pmids":["36527702"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":200},"commonTop":["Alopecia","Leukopenia","Fatigue","Anaemia","Neutropenia"]}}